Fulcrum Therapeutics Stock Price Prediction
| FULC Stock | USD 9.85 0.26 2.57% |
Momentum 53
Impartial
Oversold | Overbought |
EPS Estimate Next Quarter (0.30) | EPS Estimate Current Year (1.18) | EPS Estimate Next Year (1.20) | Wall Street Target Price 19 | EPS Estimate Current Quarter (0.29) |
Using Fulcrum Therapeutics hype-based prediction, you can estimate the value of Fulcrum Therapeutics from the perspective of Fulcrum Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Fulcrum Therapeutics using Fulcrum Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Fulcrum using crowd psychology based on the activity and movement of Fulcrum Therapeutics' stock price.
Fulcrum Therapeutics Short Interest
A significant increase or decrease in Fulcrum Therapeutics' short interest from the previous month could be a good indicator of investor sentiment towards Fulcrum. Short interest can provide insight into the potential direction of Fulcrum Therapeutics stock and how bullish or bearish investors feel about the market overall.
200 Day MA 7.5646 | Short Percent 0.0607 | Short Ratio 1.12 | Shares Short Prior Month 3.8 M | 50 Day MA 10.5392 |
Fulcrum Therapeutics Hype to Price Pattern
Investor biases related to Fulcrum Therapeutics' public news can be used to forecast risks associated with an investment in Fulcrum. The trend in average sentiment can be used to explain how an investor holding Fulcrum can time the market purely based on public headlines and social activities around Fulcrum Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Fulcrum Therapeutics' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Fulcrum Therapeutics.
Fulcrum Therapeutics Implied Volatility | 1.01 |
Fulcrum Therapeutics' implied volatility exposes the market's sentiment of Fulcrum Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Fulcrum Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Fulcrum Therapeutics stock will not fluctuate a lot when Fulcrum Therapeutics' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Fulcrum Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Fulcrum because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Fulcrum Therapeutics after-hype prediction price | USD 9.84 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Fulcrum contract
Based on the Rule 16, the options market is currently suggesting that Fulcrum Therapeutics will have an average daily up or down price movement of about 0.0631% per day over the life of the 2026-03-20 option contract. With Fulcrum Therapeutics trading at USD 9.85, that is roughly USD 0.006218 . If you think that the market is fully incorporating Fulcrum Therapeutics' daily price movement you should consider acquiring Fulcrum Therapeutics options at the current volatility level of 1.01%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Check out Fulcrum Therapeutics Basic Forecasting Models to cross-verify your projections. Fulcrum Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Fulcrum Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Fulcrum Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Fulcrum Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Fulcrum Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Fulcrum Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Fulcrum Therapeutics' historical news coverage. Fulcrum Therapeutics' after-hype downside and upside margins for the prediction period are 1.89 and 17.79, respectively. We have considered Fulcrum Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Fulcrum Therapeutics is moderately volatile at this time. Analysis and calculation of next after-hype price of Fulcrum Therapeutics is based on 3 months time horizon.
Fulcrum Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Fulcrum Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Fulcrum Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Fulcrum Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.46 | 7.95 | 0.01 | 0.82 | 23 Events / Month | 7 Events / Month | In about 23 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
9.85 | 9.84 | 0.10 |
|
Fulcrum Therapeutics Hype Timeline
Fulcrum Therapeutics is currently traded for 9.85. The entity has historical hype elasticity of -0.01, and average elasticity to hype of competition of -0.82. Fulcrum is expected to decline in value after the next headline, with the price expected to drop to 9.84. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.1%, whereas the daily expected return is currently at 0.46%. The volatility of related hype on Fulcrum Therapeutics is about 447.38%, with the expected price after the next announcement by competition of 9.03. About 76.0% of the company shares are owned by institutional investors. The book value of Fulcrum Therapeutics was currently reported as 3.67. The company recorded a loss per share of 1.14. Fulcrum Therapeutics had not issued any dividends in recent years. Given the investment horizon of 90 days the next expected press release will be in about 23 days. Check out Fulcrum Therapeutics Basic Forecasting Models to cross-verify your projections.Fulcrum Therapeutics Related Hype Analysis
Having access to credible news sources related to Fulcrum Therapeutics' direct competition is more important than ever and may enhance your ability to predict Fulcrum Therapeutics' future price movements. Getting to know how Fulcrum Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Fulcrum Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| OCGN | Ocugen Inc | (0.06) | 10 per month | 0.00 | (0.07) | 5.69 | (6.56) | 14.68 | |
| CMPX | Compass Therapeutics | 0.30 | 8 per month | 3.42 | 0.14 | 8.03 | (5.75) | 17.71 | |
| LXRX | Lexicon Pharmaceuticals | (0.03) | 7 per month | 0.00 | (0.08) | 7.04 | (6.49) | 27.27 | |
| OMER | Omeros | 0.19 | 9 per month | 4.72 | 0.13 | 15.37 | (8.85) | 171.64 | |
| RAPT | RAPT Therapeutics | 0.00 | 7 per month | 4.27 | 0.05 | 7.87 | (6.86) | 25.29 | |
| NMRA | Neumora Therapeutics | 0.04 | 8 per month | 3.91 | 0.06 | 13.85 | (7.26) | 42.94 | |
| BCYC | Bicycle Therapeutics | 0.21 | 8 per month | 0.00 | (0.07) | 6.40 | (6.20) | 17.57 | |
| LCTX | Lineage Cell Therapeutics | (0.15) | 9 per month | 3.56 | (0.01) | 6.04 | (6.08) | 15.77 | |
| ADCT | ADC Therapeutics SA | 0.55 | 12 per month | 0.00 | (0.05) | 8.49 | (7.56) | 22.84 | |
| NGNE | Neurogene | (18.82) | 9 per month | 0.00 | (0.05) | 9.78 | (12.83) | 36.95 |
Fulcrum Therapeutics Additional Predictive Modules
Most predictive techniques to examine Fulcrum price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Fulcrum using various technical indicators. When you analyze Fulcrum charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Fulcrum Therapeutics Predictive Indicators
The successful prediction of Fulcrum Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Fulcrum Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Fulcrum Therapeutics based on analysis of Fulcrum Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Fulcrum Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Fulcrum Therapeutics's related companies. | 2023 | 2024 | 2025 | 2026 (projected) | Days Sales Outstanding | 292.65 | 15.25 | 13.72 | 13.04 | PTB Ratio | 1.76 | 1.2 | 1.38 | 1.31 |
Story Coverage note for Fulcrum Therapeutics
The number of cover stories for Fulcrum Therapeutics depends on current market conditions and Fulcrum Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Fulcrum Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Fulcrum Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Fulcrum Therapeutics Short Properties
Fulcrum Therapeutics' future price predictability will typically decrease when Fulcrum Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Fulcrum Therapeutics often depends not only on the future outlook of the potential Fulcrum Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Fulcrum Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 62 M | |
| Cash And Short Term Investments | 241 M |
Complementary Tools for Fulcrum Stock analysis
When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |